Vivaldi Capital Management LP Lowers Stock Position in iShares Biotechnology ETF (NASDAQ:IBB)

Vivaldi Capital Management LP lessened its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB) by 36.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,063 shares of the financial services provider’s stock after selling 1,725 shares during the quarter. Vivaldi Capital Management LP’s holdings in iShares Biotechnology ETF were worth $424,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Guardian Wealth Advisors LLC NC boosted its stake in shares of iShares Biotechnology ETF by 24.8% in the fourth quarter. Guardian Wealth Advisors LLC NC now owns 372 shares of the financial services provider’s stock valued at $49,000 after purchasing an additional 74 shares during the period. Ally Invest Advisors Inc. boosted its stake in shares of iShares Biotechnology ETF by 5.3% in the fourth quarter. Ally Invest Advisors Inc. now owns 1,515 shares of the financial services provider’s stock valued at $200,000 after purchasing an additional 76 shares during the period. Arete Wealth Advisors LLC boosted its stake in shares of iShares Biotechnology ETF by 4.2% in the fourth quarter. Arete Wealth Advisors LLC now owns 1,990 shares of the financial services provider’s stock valued at $263,000 after purchasing an additional 80 shares during the period. TD Private Client Wealth LLC boosted its stake in shares of iShares Biotechnology ETF by 3.0% in the fourth quarter. TD Private Client Wealth LLC now owns 2,746 shares of the financial services provider’s stock valued at $363,000 after purchasing an additional 81 shares during the period. Finally, Cullen Frost Bankers Inc. boosted its stake in shares of iShares Biotechnology ETF by 1.5% in the fourth quarter. Cullen Frost Bankers Inc. now owns 5,654 shares of the financial services provider’s stock valued at $748,000 after purchasing an additional 82 shares during the period. Hedge funds and other institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Stock Performance

NASDAQ IBB opened at $122.51 on Tuesday. iShares Biotechnology ETF has a one year low of $107.43 and a one year high of $150.57. The firm has a 50 day simple moving average of $123.55 and a 200-day simple moving average of $132.50. The firm has a market cap of $5.28 billion, a price-to-earnings ratio of 23.96 and a beta of 0.77.

iShares Biotechnology ETF Increases Dividend

The company also recently declared a dividend, which was paid on Friday, March 21st. Investors of record on Tuesday, March 18th were paid a $0.1212 dividend. The ex-dividend date of this dividend was Tuesday, March 18th. This is an increase from iShares Biotechnology ETF’s previous dividend of $0.06.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.